The North America Left Atrial Appendage (LAA) Closure Device Market should witness market growth of 18.0% CAGR during the forecast period (2022-2028).
The left atrial appendage (LAA) is a tiny sac in the upper left chamber of the heart that resembles the shape of an ear. During atrial fibrillation, the electrical impulses are controlled by this sac. Left atrial appendage closure devices are percutaneous devices designed to prevent atrial fibrillation-related strokes and emboli.
Market expansion is fueled by factors such as a rise in the number of atrial intervention device approvals, an increase in the incidence of atrial fibrillation as well as heart stroke cases, a rapidly aging population, hypertension-related disorders, and lifestyle disruptions such as smoking. Moreover, growing awareness campaigns in untapped areas provide an abundance of potential opportunities for the market throughout the coming years. These factors are anticipated to propel the expansion of the left atrial appendage closure device market.
In atrial fibrillation, the heart beats irregularly, preventing it from efficiently pumping blood out of the heart and throughout the body. This causes blood to pool or accumulate in the heart, where clots may develop. A stroke can develop if a clot reaches the brain. When blood accumulates in the heart, the left atrial appendage is where it tends to pool.
The regional market is estimated to expand at a rapid rate due to a number of factors, including the high adoption of advanced left atrial appendage closure devices, the rise in the incidence of atrial fibrillation, and the country's well-developed healthcare infrastructure. The U.S. Food and Drug Administration (FDA) has authorized left atrial appendage closure (LAAC) as an alternative to anticoagulation for the prevention of stroke in individuals with nonvalvular atrial fibrillation. Due to these factors, the demand for LAAC is increasing, which is directly augmenting the growth of the left atrial appendage closure devices market in the region.
The US market dominated the North America Left Atrial Appendage (LAA) Closure Device Market by Country in 2021; thereby, achieving a market value of $1,098 million by 2028. The Canada market is experiencing a CAGR of 20.3% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 20% during (2022-2028).
Based on Application, the market is segmented into Geospatial Mapping, Disaster Management, Energy & Resource Management, Surveillance & Monitoring, and Others. Based on End-user, the market is segmented into Government, Energy, Defense, Agriculture & Forestry, Media & Entertainment, Civil Engineering & Archaeology, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, AtriCure, Inc., Abbott Laboratories, Johnson & Johnson (Johnson & Johnson Services, Inc.), Occlutech Holding AG, LifeTech Scientific Corporation, Cardia, Inc. and Lepu Medical Technology Co., Ltd
The left atrial appendage (LAA) is a tiny sac in the upper left chamber of the heart that resembles the shape of an ear. During atrial fibrillation, the electrical impulses are controlled by this sac. Left atrial appendage closure devices are percutaneous devices designed to prevent atrial fibrillation-related strokes and emboli.
Market expansion is fueled by factors such as a rise in the number of atrial intervention device approvals, an increase in the incidence of atrial fibrillation as well as heart stroke cases, a rapidly aging population, hypertension-related disorders, and lifestyle disruptions such as smoking. Moreover, growing awareness campaigns in untapped areas provide an abundance of potential opportunities for the market throughout the coming years. These factors are anticipated to propel the expansion of the left atrial appendage closure device market.
In atrial fibrillation, the heart beats irregularly, preventing it from efficiently pumping blood out of the heart and throughout the body. This causes blood to pool or accumulate in the heart, where clots may develop. A stroke can develop if a clot reaches the brain. When blood accumulates in the heart, the left atrial appendage is where it tends to pool.
The regional market is estimated to expand at a rapid rate due to a number of factors, including the high adoption of advanced left atrial appendage closure devices, the rise in the incidence of atrial fibrillation, and the country's well-developed healthcare infrastructure. The U.S. Food and Drug Administration (FDA) has authorized left atrial appendage closure (LAAC) as an alternative to anticoagulation for the prevention of stroke in individuals with nonvalvular atrial fibrillation. Due to these factors, the demand for LAAC is increasing, which is directly augmenting the growth of the left atrial appendage closure devices market in the region.
The US market dominated the North America Left Atrial Appendage (LAA) Closure Device Market by Country in 2021; thereby, achieving a market value of $1,098 million by 2028. The Canada market is experiencing a CAGR of 20.3% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 20% during (2022-2028).
Based on Application, the market is segmented into Geospatial Mapping, Disaster Management, Energy & Resource Management, Surveillance & Monitoring, and Others. Based on End-user, the market is segmented into Government, Energy, Defense, Agriculture & Forestry, Media & Entertainment, Civil Engineering & Archaeology, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, AtriCure, Inc., Abbott Laboratories, Johnson & Johnson (Johnson & Johnson Services, Inc.), Occlutech Holding AG, LifeTech Scientific Corporation, Cardia, Inc. and Lepu Medical Technology Co., Ltd
Scope of the Study
By End-use
- Hospital
- Ambulatory Surgery Centers
- Others
By Product
- Endocardial LAA Devices
- Epicardial LAA Devices
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Boston Scientific Corporation
- AtriCure, Inc.
- Abbott Laboratories
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Occlutech Holding AG
- LifeTech Scientific Corporation
- Cardia, Inc.
- Lepu Medical Technology Co., Ltd
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. North America Left Atrial Appendage (LAA) Closure Device Market by End-use
Chapter 4. North America Left Atrial Appendage (LAA) Closure Device Market by Product
Chapter 5. North America Left Atrial Appendage (LAA) Closure Device Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Boston Scientific Corporation
- AtriCure, Inc.
- Abbott Laboratories
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Occlutech Holding AG
- LifeTech Scientific Corporation
- Cardia, Inc.
- Lepu Medical Technology Co., Ltd
Methodology
LOADING...
